Polyarticular juvenile idiopathic arthritis

disease

On this page

Also known as juvenile polyarthritisjuvenile polyarticular arthritispolyarticular JIA

Summary

Polyarticular juvenile idiopathic arthritis (MONDO:0018456) is a disease and 8 clinical trials. Top therapeutic interventions include methotrexate. A subtype of juvenile idiopathic arthritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	polyarticular juvenile idiopathic arthritis
Mondo ID	MONDO:0018456
EFO	EFO:0009730
Orphanet	404580
SNOMED CT	16044751000119106
UMLS	C4521004
MedGen	1622195
GARD	0021729
Is cancer (heuristic)	no

Also known as: juvenile polyarthritis · juvenile polyarticular arthritis · polyarticular JIA

Disease family

This is a subtype of juvenile idiopathic arthritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › connective tissue disorder › rheumatic disorder › juvenile idiopathic arthritis › polyarticular juvenile idiopathic arthritis

Subtypes (2): rheumatoid factor-negative juvenile idiopathic arthritis, rheumatoid factor-positive polyarticular juvenile idiopathic arthritis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Abatacept	Approved (phase 4)
Tocilizumab	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE1	2
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07428551	PHASE4	COMPLETED	Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients
NCT00144625	PHASE3	COMPLETED	Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
NCT07184450	PHASE1	RECRUITING	Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
NCT04018599	PHASE1	COMPLETED	Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
NCT05754710	Not specified	RECRUITING	Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
NCT07553910	Not specified	NOT_YET_RECRUITING	Tenosynovitis in Polyarticular and Oligoarticular Juvenile Idiopathic Arthritis
NCT02141984	Not specified	COMPLETED	Surveillance of Humira in Korean JIA Patients
NCT05411211	Not specified	COMPLETED	An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
METHOTREXATE	4	1

Drugs: Methotrexate